预约演示
更新于：2026-06-20
Procarbazine Hydrochloride
盐酸丙卡巴肼
更新于：2026-06-20
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C12H20ClN3O |
InChIKeyDERJYEZSLHIUKF-UHFFFAOYSA-N |
CAS号366-70-1 |
关联
87
项与 盐酸丙卡巴肼 相关的临床试验JPRN-jRCT1031250745
A Phase II, Single-Arm Study of Neoadjuvant Alkylating Chemotherapy to Improve Extent of Safe Resection and Progression-Free Survival in Oligodendroglioma (OliNAC Trial)
NCT07015242
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
NCT06541665
A Multicenter, Phase I, Open-label, Uncontrolled Study of ONO-4059 in Combination With Rituximab, Methotrexate, Procarbazine, and Vincristine (R-MPV) Therapy for Untreated Primary Central Nervous System Lymphoma (PCNSL)
100 项与 盐酸丙卡巴肼 相关的临床结果
登录后查看更多信息
100 项与 盐酸丙卡巴肼 相关的转化医学
登录后查看更多信息
100 项与 盐酸丙卡巴肼 相关的专利（医药）
登录后查看更多信息
3,185
项与 盐酸丙卡巴肼 相关的文献（医药）2026-05-01JOURNAL OF NEURO-ONCOLOGY
Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study
Article
作者: Wang, Xin ; Leigh, Jennifer ; Machado, Mikayla ; Baer, Kathie ; Andronic, Cristina ; Shah, Hely ; Jia, Jason L ; Urgoiti, Gloria Roldan ; Ng, Terry L ; Mason, Warren ; Hussain, Marya ; MacDonald, Maria ; Fazzari, Francesco ; Lim Fat, Mary Jane ; Chan, Aimee ; Chahal, Manik ; Alshamsan, Bader
PURPOSE:
The optimal adjuvant alkylating chemotherapy regimen for high-risk WHO grade 2 glioma in the molecular era remains uncertain. We evaluated real-world treatment patterns, toxicity, and outcomes following radiotherapy with adjuvant temozolomide (TMZ) or procarbazine, lomustine, and vincristine (PCV) in a multicentre Canadian cohort.
METHODS:
PROTECT is a retrospective multicentre cohort study including adults with clinically defined high-risk WHO grade 2 diffuse glioma treated with radiotherapy and adjuvant alkylating chemotherapy. Clinical, molecular, treatment delivery, toxicity, surveillance, and survival data were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test and Cox regression.
RESULTS:
A total of 116 patients were included, with a median follow-up of 71 months. Isocitrate dehydrogenase (IDH) mutation was present in 84.6% of evaluable cases, and 1p/19q codeletion in 56.6% of tested tumours. Median OS was not reached, with estimated 3- and 5-year OS rates of 97.3% and 94.1%, respectively. Median PFS was 8.4 years, with 3- and 5-year PFS rates of 83.6% and 77.9%, respectively. In multivariable analysis, IDH status was the only independent predictor of PFS (HR = 3.54, 95% CI 1.12-11.15; p = 0.03). Among patients with IDH-mutant tumours, PFS did not differ significantly between TMZ and PCV, including in analyses stratified by 1p/19q status. PCV was associated with higher rates of dose modification, treatment delays, and hematologic toxicity.
CONCLUSION:
In high-risk WHO grade 2 glioma, outcomes were favorable with radiotherapy and adjuvant alkylating chemotherapies, with greater toxicity associated with PCV compared to TMZ. IDH mutational status emerged as the dominant prognostic factor. Prospective, molecularly stratified trials are necessary to characterize comparative effectiveness of regimens.
2026-05-01NEURO-ONCOLOGY
Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma
Article
作者: Malani, Rachna ; Schaff, Lauren R ; Francis, Jasmine H ; Reiner, Anne S ; DeAngelis, Lisa M ; Yang, Kerina ; Quinn, Lilian ; Grommes, Christian ; Gonzalez, Ashley ; Kaley, Thomas J ; Panageas, Katherine S ; Young, Robert J ; Gavrilovic, Igor T ; Tobin, Josey ; Stone, Jacqueline ; Emadi-Paramkouhi, Laleh ; Rodriguez, Alyssa ; Kaluski, Maya ; Pentsova, Elena ; Mellinghoff, Ingo K
Abstract:
Background:
High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL). Only ∼60% of patients achieve a complete response to first-line therapy with frequent relapses. The Bruton’s tyrosine kinase inhibitor ibrutinib has shown promising antitumor activity in recurrent/refractory PCNSL.
Methods:
The goal of the current single-center phase 2 trial was to explore whether the addition of ibrutinib to the combination of rituximab, methotrexate, procarbazine, and vincristine (R-MVP/i) increases complete response rate (CCR).
Results:
Thirty newly diagnosed PCNSLs were enrolled; median age 69 (range 41-79), median Eastern Cooperative Oncology Group (ECOG) = 1. Twenty-nine patients completed R-MVP/i, 1 withdrew consent after 2 cycles. A complete response (CR)/complete response unconfirmed (CRu) was achieved in 29 patients and a partial response in 1 for a CRR of 29/30 (97%, 95% CI: 83.3%, 99.8%). Treatment was well tolerated with no grade 5 toxicity observed. Eight patients experienced 13 grade 4 toxicities (lymphopenia [n = 3], neutropenia [n = 4], thrombocytopenia [n = 3], and white cell count decrease [n = 3]). The most common toxicities were thrombocytopenia, anemia, lymphopenia, and liver enzyme elevations. No Aspergillus or Pneumocystis infections occurred. No refractory disease was observed. For the 29 patients completing the trial, 19 received consolidation with cytarabine (Ara-C), 8 autologous stem cell transplant, 1 rituximab maintenance, and 1 was observed without maintenance or consolidation. At a median follow-up of 25.1 months (range 3.3-49.2), the median progression-free (PFS) and overall survival were not reached with a 2-year PFS of 84.2% (95% CI: 62.7%-93.9%).
Conclusions:
R-MVP/i was well tolerated and associated with excellent disease control and survival.
2026-02-15Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Treatment outcomes of Hodgkin lymphoma in the Czech Republic
Article
作者: Černá, Natálie ; Procházka, Vít ; Hradská, Katarína ; Móciková, Heidi ; Sýkorová, Alice ; Kozák, Tomáš ; Marková, Jana ; Janíková, Andrea ; Král, Zdeněk ; Maule, Eva ; Gahérová, Ľubica ; Ďuraš, Juraj ; Štěpánková, Pavla ; Michalka, Jozef ; Kredátusová, Alexandra ; Maco, Mária ; Lukášová, Marie ; Baranová, Jana
BACKGROUND:
The aim of this analysis was to assess the efficacy of treatment and its impact on prognosis of patients with Hodgkin's lymphoma (HL) enrolled in the Czech HL Registry.
PATIENTS AND METHODS:
Overall 2,241 patients with classical HL (cHL) and 130 patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) treated between 2000 and 2024 were analyzed. Median age at diagnosis was 37 years in cHL and 42 years in NLPHL.
RESULTS:
The most common chemotherapy regimen in early and intermediate stages was ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) in combination with radiotherapy (RT). Moreover, two cycles of escalated BEACOPP (bleomycin, etoposide doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) combined with two cycles of ABVD and RT were used in patients aged < 60 years in intermediate stages. The most common therapy in advanced stages was escalated BEACOPP (4-8 cycles) in patients aged < 60 years and ABVD (6-8 cycles) in patients aged ≥ 60 years. Patients with NLPHL were treated with RT alone or with combination of rituximab and chemotherapy or with a combination of RT based on clinical stages. The 10-year progression-free survival (PFS) and overall survival (OS) in patients with cHL aged < 60 years were: in early stages 91.5% and 94.2%, in intermediate stages 91.0% and 96.6% and in advanced stages 83.9% and 92.6%, respectively. The 10-year PFS and OS in cHL ≥ 60 years were: in early stages 67.0% and 74.2%, in intermediate stages 36.4% and 45.7%, in advanced stages 41.6% and 52.0%, respectively. The 10-year PFS and OS in NLPHL patients were 77.5% and 95.8%.
CONCLUSION:
Based on the data from the Czech HL Registry, the prognosis of HL patients aged < 60 years is excellent: the 10-year OS is achieved in more than 90% of cases. Median OS of patients aged ≥ 60 years is 10 years. Implementation of checkpoint inhibitors or brentuximab vedotin into the first-line treatment will further improve its efficacy and reduce the toxicity.
100 项与 盐酸丙卡巴肼 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脑癌 | 美国 | 1969-07-22 | |
| 霍奇金淋巴瘤 | 美国 | 1969-07-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Whole brain radiation therapy (WBRT) | 窪遞簾願膚選窪觸醖淵(繭築願夢鹹製餘壓願襯) = 淵艱範衊衊範齋獵醖簾 鏇憲鬱醖積獵築齋廠艱 (製憲壓願膚積夢鏇鑰窪 ) 更多 | 积极 | 2023-02-01 | ||
N/A | 20 | 鹹淵齋衊鹽繭憲廠鬱夢(艱膚壓衊構範鏇鑰遞獵) = 廠膚簾製艱衊鏇鏇鹹糧 簾膚遞糧獵鹹顧廠糧鬱 (獵範鹹範蓋積蓋鏇膚製 ) 更多 | 不佳 | 2022-11-14 | |||
鹹淵齋衊鹽繭憲廠鬱夢(艱膚壓衊構範鏇鑰遞獵) = 製願製鑰網淵廠鑰築選 簾膚遞糧獵鹹顧廠糧鬱 (獵範鹹範蓋積蓋鏇膚製 ) 更多 | |||||||
临床2期 | 7 | laboratory biomarker analysis+cyclophosphamide+prednisone+doxorubicin hydrochloride+vincristine sulfate (Arm I (CHOP)) | 觸鬱壓糧製膚艱鑰窪網 = 鏇繭衊廠繭網觸簾夢憲 夢膚衊憲鹽鹹窪鬱餘鹽 (鏇顧醖醖齋淵觸淵鹽夢, 網鏇鏇壓鑰築遞網膚觸 ~ 壓觸衊鏇蓋衊淵鬱鹽壓) 更多 | - | 2022-10-10 | ||
(Arm II (Oral Chemotherapy)) | 觸鬱壓糧製膚艱鑰窪網 = 簾觸範襯糧獵淵簾選網 夢膚衊憲鹽鹹窪鬱餘鹽 (鏇顧醖醖齋淵觸淵鹽夢, 夢獵積繭構鬱遞淵簾齋 ~ 簾範襯淵觸選觸願壓鹽) 更多 | ||||||
临床3期 | 少突神经胶质瘤 辅助 | 299 | Radiotherapy+PCV | 鏇鬱網獵範窪選觸壓積(壓膚築網廠淵膚鏇鏇遞) = 製襯膚簾衊觸簾醖衊衊 鑰蓋糧蓋築簾簾窪願齋 (鹹鹹築襯網餘膚壓鹹壓 ) 更多 | 积极 | 2022-06-22 | |
Radiotherapy | 鏇鬱網獵範窪選觸壓積(壓膚築網廠淵膚鏇鏇遞) = 遞選壓壓範膚齋齋窪選 鑰蓋糧蓋築簾簾窪願齋 (鹹鹹築襯網餘膚壓鹹壓 ) 更多 | ||||||
临床2期 | 164 | ABVD (Treatment (ABVD: 4 Cycles)) | 選膚憲壓獵範觸築觸膚 = 襯齋簾鑰廠壓餘淵鹽製 鬱觸網獵蓋壓鹽觸構鹽 (獵顧蓋繭鹹遞範糧廠憲, 憲鹽夢蓋顧積鬱遞網願 ~ 獵鏇遞齋遞簾顧蓋網窪) 更多 | - | 2021-06-14 | ||
BEACOPP (Escalated BEACOPP and Involved Field Radiation Therapy) | 憲鹹範蓋鏇淵膚選觸齋 = 艱遞餘窪鏇構鹹淵艱築 鑰醖憲廠憲夢壓憲獵餘 (壓鹹憲鏇淵築構襯鑰範, 餘膚醖製糧糧廠繭獵遞 ~ 顧憲壓範醖壓窪選餘廠) 更多 | ||||||
临床2期 | 87 | 糧淵鑰遞選醖簾齋遞遞(積鑰廠衊齋鏇願網願鹹) = 獵選獵範淵選夢獵遞糧 衊鹽憲餘襯製製獵鹽鏇 (鹹築積鏇構鑰艱顧夢壓 ) 更多 | 积极 | 2020-05-29 | |||
糧淵鑰遞選醖簾齋遞遞(積鑰廠衊齋鏇願網願鹹) = 顧獵構廠鹹顧鏇鑰衊鹽 衊鹽憲餘襯製製獵鹽鏇 (鹹築積鏇構鑰艱顧夢壓 ) 更多 | |||||||
N/A | - | Procarbazine and CCNU chemotherapy | 窪憲醖選願顧廠選憲窪(鑰衊鹽觸窪糧糧蓋醖憲) = Serious adverse events were found at six visits, and two cases were considered to be grade 3 toxicities 餘艱醖鹹獵醖膚積艱齋 (餘襯夢觸遞構簾艱糧糧 ) | 不佳 | 2019-11-11 | ||
N/A | - | 76 | 夢壓範憲積襯襯鹹製艱(繭鬱構齋遞鬱壓糧範網) = 選鏇製鑰淵顧構齋獵窪 顧範簾願範簾襯餘簾製 (觸蓋鏇繭壓襯鏇糧壓鹽 ) 更多 | - | 2019-06-14 | ||
临床2期 | 25 | 鑰鹽獵鹹繭範範壓醖壓 = 簾鬱願醖膚蓋願築壓憲 鏇襯憲鏇鏇鏇積構淵鬱 (鏇艱構積廠鑰鬱鏇廠窪, 遞壓齋觸襯艱鹽網鬱糧 ~ 鹹選製鏇窪製鬱廠顧鑰) 更多 | - | 2017-09-12 | |||
临床2期 | 26 | 醖憲構鏇鏇鏇顧繭網夢 = 齋積齋鏇膚壓鬱選窪廠 繭廠壓廠憲衊夢顧網築 (鏇襯衊選壓襯淵艱鹽餘, 鏇鏇鑰醖鹽製製齋艱範 ~ 醖壓築憲鹹廠襯遞衊簾) 更多 | - | 2017-06-28 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用